Psychedelic Medicine

Association

Psilocybin in pharmacotherapy of obsessive-compulsive disorder

Excerpts from the publication

Obsessive-compulsive disorder (OCD) is a chronic mental disease that affects approximately 2% of the population. Obsessions and compulsions are troublesome for patients and may disturb their everyday activities. The pathogenesis of this disease is still not fully elucidated, but dysfunctions of serotonin-, dopamine- and glutamate-mediated neurotransmission together with early maladaptive schemas seem of importance. Pharmacological treatment includes drugs affecting the serotoninergic, dopaminergic, and glutamatergic systems, such as selective serotonin reuptake inhibitors (SSRIs). Providing that up to 40% of patients with OCD are resistant to the currently available medications, there is a need for novel and effective therapies. Recent discoveries suggest that psilocybin, a non-physically addictive psychoactive substance, may ameliorate disease symptoms. When used in appropriate doses and under strict clinical control, psilocybin appears as a valuable treatment for OCD. This narrative article provides a thorough overview of OCD’s etiology, current treatment options, and the emerging evidence supporting psilocybin’s efficacy in managing OCD symptoms.

Read more

Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default

Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions

Scoping Review: The Role of Psychedelics in the Management of Chronic Pain

Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness

Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments

Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission